Global Malignant Pleural Mesothelioma Market Report By Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Oncology Centers) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2019-2026

ID:VMR11211972

April 2020

Report Formats:

Choose your Buying Option

Single User License: $ 3950.00

Upto 10 Users License: $ 4950.00

Enterprise License: $ 8600.00

Data Pack: $ 2100.00

Buy Now

Description
Table Of Content

The global demand for Malignant Pleural Mesothelioma Market is presumed to reach the valuation of nearly USD XXX MN by 2026 from USD XXX MN in 2019 with a CAGR of X.XX% under the study period of 2020 - 2026.

Pleural Mesothelioma is a malignant tumour which develops in the lining of the pleura I. E. The lungs. This tumour is caused by continuous exposure to asbestos fibres. Prolonged exposure to asbestos causes inflammation of the pleura which gradually develops into a tumour. This tumour can develop if a person is exposed to asbestos for 10-50 years.Among all the types of Mesothelioma, this is the most common type of tumour. The symptoms of this disease are similar to any respiratory disease along with the symptoms of cancer. This tumour can be detected using scans, biopsy and thoracoscopy. If detected at the later stages the life expectancy can be between 6-12 months. The usual treatment methods involve surgery, chemotherapy and radiation with the removal of a lung in worst-case. This is an incurable disease but emerging clinical trials can improve a patient's life expectancy.

Market Dynamics

The market of malignant pleural Mesothelioma is expected to grow due to the increase in the investment in construction sectors. Asbestos exposure to the workers on the construction site such as plumbers, electricians etc. can lead to such diseases. The increase in the commercial production of asbestos and asbestos-based consumer products can boost the growth of this market. The rise in geriatric population can as well fuel this market since the risk of this disease is higher among the old and can as well affect the family members of people in close contact with asbestos. This market will see a peak during COVID-19 times due to increase in infrastructural development to enable handling the large volume of patients in certain geographical areas. The main challenge faced by this market will be stringent rules put forth by the government for the asbestos industry owing to its carcinogenic effect.

The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.

Additionally, these tools also give inclusive assessment of each application/product segment in the global market of malignant pleural mesothelioma.

Market Segmentation

The entire malignant pleural mesothelioma market has been sub-categorized into drug type, route of administration and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.

By Drug Type

By Route of Administration

Oral
Parenteral

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Oncology Centers

Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for malignant pleural mesothelioma market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

Europe Malignant Pleural Mesothelioma Market By Revenue (USD MN)

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the malignant pleural mesothelioma market include AstraZeneca Plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, BoehringerIngelheim GmbH, Mylan N.V., Others. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

METHODOLOGY:

This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.

If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.

1 . PREFACE
       1.1. Report Description
           1.1.1. Objective
           1.1.2. Target Audience
           1.1.3. Unique Selling Proposition (USP) & offerings
       1.2. Research Scope
       1.3. Research Methodology
           1.3.1. Market Research Process
           1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY
       2.1. Highlights of Malignant Pleural Mesothelioma Market
       2.2. Global Malignant Pleural Mesothelioma Market Snapshot

3 . MALIGNANT PLEURAL MESOTHELIOMA – INDUSTRY ANALYSIS
       3.1. Introduction
       3.2. Market Drivers of Malignant Pleural Mesothelioma Market
       3.3. Market Restraints of Malignant Pleural Mesothelioma Market
       3.4. Opportunities of Malignant Pleural Mesothelioma Market
       3.5. Trends of Malignant Pleural Mesothelioma Market
       3.6. Porter’s Five Force Analysis of Malignant Pleural Mesothelioma Market
       3.7. Malignant Pleural Mesothelioma Market Attractiveness Analysis
           3.7.1 Market Attractive Analysis by Drug Type
           3.7.2 Market Attractive Analysis by Route of Administration
           3.7.3 Market Attractive Analysis by Distribution Channel
           3.7.4 Market Attractive Analysis by Region

4 . VALUE CHAIN ANALYSIS
       4.1. Malignant Pleural Mesothelioma Value Chain Analysis
       4.2. Malignant Pleural Mesothelioma Raw Material Analysis
           4.2.1. List of Raw Materials
           4.2.2. Malignant Pleural Mesothelioma Raw Material Manufactures List
           4.2.3. Price Trend of Malignant Pleural Mesothelioma Key Raw Materials
       4.3. List of Potential Buyers
       4.4. Marketing Channel
           4.4.1. Direct Marketing
           4.4.2. Indirect Marketing
           4.4.3. Marketing Channel Development Trend

5 . GLOBAL MALIGNANT PLEURAL MESOTHELIOMA MARKET ANALYSIS BY DRUG TYPE
       5.1 Overview by Drug Type
       5.2 Global Malignant Pleural Mesothelioma Market Analysis by Drug Type
       5.3 Market Analysis of Pemetrexed by Regions
       5.4 Market Analysis of Cisplatin by Regions
       5.5 Market Analysis of Carboplatin by Regions
       5.6 Market Analysis of Gemcitabine by Regions
       5.7 Market Analysis of Vinorelbine by Regions
       5.8 Market Analysis of Others by Regions

6 . GLOBAL MALIGNANT PLEURAL MESOTHELIOMA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
       6.1 Overview by Route of Administration
       6.2 Global Malignant Pleural Mesothelioma Market Analysis by Route of Administration
       6.3 Market Analysis of Oral by Regions
       6.4 Market Analysis of Parenteral by Regions

7 . GLOBAL MALIGNANT PLEURAL MESOTHELIOMA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
       7.1 Overview by Distribution Channel
       7.2 Global Malignant Pleural Mesothelioma Market Analysis by Distribution Channel
       7.3 Market Analysis of Hospital Pharmacies by Regions
       7.4 Market Analysis of Retail Pharmacies by Regions
       7.5 Market Analysis of Oncology Centers by Regions

8 . GLOBAL MALIGNANT PLEURAL MESOTHELIOMA MARKET ANALYSIS BY GEOGRAPHY
       8.1. Regional Outlook
       8.2. Introduction
       8.3. North America
           8.3.1. Overview
           8.3.2. North America Malignant Pleural Mesothelioma Market Estimate by Country
           8.3.3. United State
           8.3.4. Rest of North America
       8.4. Europe
           8.4.1. Overview
           8.4.2. Europe Malignant Pleural Mesothelioma Market Estimate by Market Segment
           8.4.3. Europe Malignant Pleural Mesothelioma Market Estimate by Country
           8.4.4. United Kingdom
           8.4.5. France
           8.4.6. Germany
           8.4.7 Rest of Europe
       8.5. Asia Pacific
           8.5.1. Overview
           8.5.2. Asia Pacific Malignant Pleural Mesothelioma Market Estimate by Market Segment
           8.5.3. Asia Pacific Malignant Pleural Mesothelioma Market Estimate by Country
           8.5.4. China
           8.5.5. Japan
           8.5.6. India
           8.5.7. Rest of Asia Pacific
       8.6. Latin America
           8.6.1. Overview
           8.6.2. Latin America Malignant Pleural Mesothelioma Market Estimate by Market Segment
           8.6.3. Latin America Malignant Pleural Mesothelioma Market Estimate by Country
           8.6.4. Brazil
           8.6.5. Rest of Latin America
       8.7. Middle East & Africa
           8.7.1. Overview
           8.7.2. Middle East & Africa Malignant Pleural Mesothelioma Market Estimate by Market Segment
           8.7.3. Middle East & Africa Malignant Pleural Mesothelioma Market Estimate by Country
           8.7.4. Middle East
           8.7.5. Africa

9 . COMPETITIVE LANDSCAPE OF THE MALIGNANT PLEURAL MESOTHELIOMA COMPANIES
       9.1. Malignant Pleural Mesothelioma Market Competition
       9.2. Partnership/Collaboration/Agreement
       9.3. Merger And Acquisitions
       9.4. New Product Launch
       9.5. Other Developments

10 . COMPANY PROFILES OF MALIGNANT PLEURAL MESOTHELIOMA INDUSTRY
       10.1. Company Share Analysis
       10.2. Market Concentration Rate
       10.3. AstraZeneca Plc.
           10.3.1. Company Overview
           10.3.2. Financials
           10.3.3. Products
           10.3.4. Recent Developments
       10.4. Bristol-Myers Squibb Company
           10.4.1. Company Overview
           10.4.2. Financials
           10.4.3. Products
           10.4.4. Recent Developments
       10.5. F. Hoffmann-La Roche Ltd.
           10.5.1. Company Overview
           10.5.2. Financials
           10.5.3. Products
           10.5.4. Recent Developments
       10.6. Merck & Co., Inc.
           10.6.1. Company Overview
           10.6.2. Financials
           10.6.3. Products
           10.6.4. Recent Developments
       10.7. Novartis AG
           10.7.1. Company Overview
           10.7.2. Financials
           10.7.3. Products
           10.7.4. Recent Developments
       10.8. Pfizer Inc.
           10.8.1. Company Overview
           10.8.2. Financials
           10.8.3. Products
           10.8.4. Recent Developments
       10.9. Sanofi
           10.9.1. Company Overview
           10.9.2. Financials
           10.9.3. Products
           10.9.4. Recent Developments
       10.10. Eli Lilly and Company
           10.10.1. Company Overview
           10.10.2. Financials
           10.10.3. Products
           10.10.4. Recent Developments
       10.11. Teva Pharmaceuticals
           10.11.1. Company Overview
           10.11.2. Financials
           10.11.3. Products
           10.11.4. Recent Developments
       10.12. BoehringerIngelheim GmbH
           10.12.1. Company Overview
           10.12.2. Financials
           10.12.3. Products
           10.12.4. Recent Developments
       10.13. Mylan N.V.
           10.13.1. Company Overview
           10.13.2. Financials
           10.13.3. Products
           10.13.4. Recent Developments
       10.14. Others
           10.14.1. Company Overview
           10.14.2. Financials
           10.14.3. Products
           10.14.4. Recent Developments

*Note - In company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

LIST OF FIGURES

Research Scope of Malignant Pleural Mesothelioma Report
Market Research Process
Market Research Methodology
Global Malignant Pleural Mesothelioma Market Size, by Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis by Drug Type
Market Attractiveness Analysis by Route of Administration
Market Attractiveness Analysis by Distribution Channel
Market Attractiveness Analysis by Region
Value Chain Analysis
Global Malignant Pleural Mesothelioma Market Analysis by Drug Type (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Pemetrexed by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Cisplatin by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Carboplatin by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Gemcitabine by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Vinorelbine by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Others by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis by Route of Administration (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Oral by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Parenteral by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis by Distribution Channel (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Hospital Pharmacies by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Retail Pharmacies by Geography (USD MN)
Global Malignant Pleural Mesothelioma Market Analysis in Oncology Centers by Geography (USD MN)
Latin America Malignant Pleural Mesothelioma Market by Revenue
Middle East & Africa Malignant Pleural Mesothelioma Market by Revenue
Recent Development in Malignant Pleural Mesothelioma Industry
Company Market Share Analysis, 2019

* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Choose your Buying Option

Single User License: $ 3950.00

Upto 10 Users License: $ 4950.00

Enterprise License: $ 8600.00

Data Pack: $ 2100.00

Buy Now

Objectives of Study

Define and measure the global market
Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
Analyze and identify major market trends along with the factors driving or inhibiting the market growth
Study the company profiles of the major market players with their market share
Analyze competitive developments

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

Buy sections of this report
Buy country level reports
Request for historical data
Request discounts available for Start-Ups & Universities

Request for Special Pricing

Why Choose Us

Client First Policy

Excellent Quality

Robust After Sales Support

24/7 Email Support

Clients

Testimonials

" Doing business with Value Market Research was – quick, easy and accurate. We got what we expected. The team was very helpful and processes were altered for our convenience. The whole process from understanding our niche requirements to delivery to after sales was excellent. "

Vincenzo Baydar – Head Planning, Leading Food Chain, US

" Excellent work!! Working with you has been easy and direct. Your flexibility to alter the report scope and timely delivery assisted me in delivering my project proposal on time. "

Mia Tang, Director - Business Strategy, Steel Industry, Germany

" This is our second purchase and we have been obliged by the service. We appreciate the efforts put by Value Market Research in terms of understanding our needs, expanding the scope of the study, delivery and handling after sales queries. "

ID:VMR11211972

April 2020

Report Formats:

Choose your Buying Option

Choose your Buying Option

Objectives of Study

Buy Chapters or Sections

Why Choose Us

Client First Policy

Excellent Quality

Robust After Sales Support

24/7 Email Support

Clients

Testimonials

Vincenzo Baydar – Head Planning, Leading Food Chain, US

Mia Tang, Director - Business Strategy, Steel Industry, Germany

Jo Chin, Owner of a Manufacturing Plant in Taiwan

Key questions answered by the report

Need specific market information?

ID:VMR11211972

April 2020

Report Formats:

Choose your Buying Option

Choose your Buying Option

Objectives of Study

Buy Chapters or Sections

Why Choose Us

Client First Policy

Excellent Quality

Robust After Sales Support

24/7 Email Support

Clients

Testimonials

Vincenzo Baydar – Head Planning, Leading Food Chain, US

Mia Tang, Director - Business Strategy, Steel Industry, Germany

Jo Chin, Owner of a Manufacturing Plant in Taiwan

Key questions answered by the report

Need specific market information?

Important: Covid19 pandemic market impact